Top Stories

Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested in lipid management near and far, and we cannot wait for you to take advantage of all the offerings! Here are some of the plans for 2023:

Jacksonville, Florida - (August 25, 2022) - The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. The new Expert Consensus Decision Pathway provides practical guidance for lowering LDL-C with nonstatin therapies.

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-Cholesterol. Inclisiran is the first FDA-approved small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.